ABVC BioPharma (ABVC) vs aTyr Pharma (ATYR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ABVC BioPharma (ABVC) has outperformed aTyr Pharma (ATYR) over the past year, losing 69.8% versus a loss of 74.5%. Over five years, ABVC leads with a -96.3% price change compared with -97.1% for ATYR. ABVC BioPharma is the larger company by market cap ($26.2 million vs $25.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVC | ATYR |
|---|---|---|
| Share price | $0.98 | $0.2553 |
| Market cap | $26.16M | $25.04M |
| 1-day change | -2.00% | -8.26% |
| YTD return | -53.99% | -67.39% |
| 1-year return | -69.75% | -74.47% |
| 5-year return | -96.31% | -97.07% |
| EPS (TTM) | $-0.30 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.33 | $1.12 |
| 52-week low | $0.707 | $0.25 |
| Distance from 52-week high | -70.54% | -77.21% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +1020.25% |
| Average volume | 111.36K | 3.24M |
| Shares outstanding | 26.69M | 98.09M |
| Employees | 16 | 58 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ABVC BioPharma
ABVC stock →ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Healthcare · Biotechnology · 16 employees
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Healthcare · Biotechnology · 58 employees
ABVC vs ATYR FAQ
Which is bigger, ABVC BioPharma or aTyr Pharma?
ABVC BioPharma (ABVC) is larger, with a market capitalization of $26.16M compared with $25.04M for aTyr Pharma (ATYR).
Which stock has performed better over the past year, ABVC or ATYR?
ABVC returned -69.75% over the past 12 months, compared with -74.47% for ATYR (price return, excluding dividends). Past performance does not predict future results.
Are ABVC BioPharma and aTyr Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.